1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Key Pharma News 16 MARCH 2015

Key Pharma News 16 MARCH 2015

  • March 2015
  • -
  • Espicom Business Intelligence
  • -
  • 40 pages

Industry Trend Analysis - J&J Poised For Pharmaceutical Acquisition
Industry Trend Analysis - BMS Highlights Potential Of Cancer Vaccines With Bavarian Nordic Deal
Industry Brief - Eisai/Merck Collaborate To Explore Keytruda, Lenvima And Halaven Combination Regimens
Industry Brief - Natco Enters Licensing Agreement With Gilead
Industry Trend Analysis - Universal Cancer Diagnostics Edging Closer To Market
Industry Trend Analysis - Novartis Will Maximise GSK Oncology Revenues
Industry Trend Analysis - AstraZeneca Takes Anti-Infectives Out of Focus Against Industry-Wide Trend Of Revival
Industry Brief - Sun Pharma To Buy GSK's Opiates Business In Australia
Industry Brief - Takeda Names Weber As CEO
Industry Brief - GSK Establishes New Global HQ For Asia In Singapore
Industry Brief - Shire Adds Rare GI Disease Product To Pipeline With Meritage Acquisition
Industry Brief - Baxter Selects Site For Baxalta's Global Headquarter
Industry Trend Analysis - G&W Well Placed To Acquire Teva Facility
Industry Brief - AstraZeneca Completes Purchase Of Actavis' Branded Respiratory Assets
Industry Trend Analysis - AbbVie Makes Surprise Acquisition Of Pharmacyclics
Industry Brief - Arrowhead Acquires Novartis' RNAi R&D Portfolio
Industry Brief - Mylan Completes Abbott Acquisition
Industry Brief - Baxter Acquires SuppreMol
Industry Brief - Targacept/Catalyst To Create Protease-Based Haemostasis/Anti-Complement Company
Industry Trend Analysis - New Acquisitions And New Corporate Identity To Reshape Impax
Industry Trend Analysis - Anti-PD1 Race Continues Despite BMS' NSCLC Approval Win
Industry Trend Analysis - Zarxio's Approval Will See Focus Shift To Battle For Market Acceptance
Industry Trend Analysis - Nonorphan Drugs Commanding Orphan Drug Prices To Increase Pressure On US
Industry Trend Analysis - Sanofi's Lantus Successor Will See EC Approval And US Launch In Q215
Industry Brief - EC Approves Xydalba For ABSSSIs In Adults
Industry Trend Analysis - Cresemba's Double Approval Will Make It Standard-Of-Care For Fungal Disease
Industry Brief - FDA Accepts For Review NDA For Teva's Abuse-Deterrent Hydrocodone ER
Industry Trend Analysis - Costs Of Treating MS To Rise In US
Industry Brief - Abraxane Gains EU Approval For First-Line NSCLC
Industry Brief - Celltrion Launches Remsima In Europe
Industry Brief - Zelboraf Launched In Japan
Industry Trend Analysis - Xadago's Approval Will Not Address Need For Disease-Modifying Parkinson's Drugs
Industry Trend Analysis - Prevenar 13 To Increase Dominance With Expanded Indication
Industry Brief - CHMP Recommends Expanded Vectibix Use
Industry Trend Analysis - Opdivo Set To Become First PD-1 Inhibitor On NSCLC Market Ahead Of Keytruda
Industry Brief - Eisai's Aricept NDA For Severe AD Accepted For Review In China
Industry Brief - EMA Accepts Kyprolis MAA For Relapsed MM
Industry Brief - BI Submits Idarucizumab BLA As Specific Reversal Agent For Pradaxa
Industry Brief - Actelion's NDA For Uptravi Accepted By FDA With Standard Review Time
Industry Brief - Zykadia Gains CHMP Positive Opinion For ALK+ NSCLC Previously Treated With Crizotinib
Industry Brief - Taiho Submits TAS-102 MAA To EMA For Refractory MCRC
Industry Brief - BI Submits Idarucizumab Applications In US/EU/Canada
Industry Brief - Glenmark Launches Trandolapril+Verapamil In US
Industry Brief - FDA Accepts Spectrum's NDA Filing For Captisol-Enabled Melphalan
Industry Brief - FDA Approves Unituxin For Paediatric High-Risk Neuroblastoma
Industry Trend Analysis - Gilead's TAF-Based Regimen To Combat Increasing Pressure From ViiV Healthcare
Industry Trend Analysis - Controversial Data Suggest Advantage For Contrave In Obesity Market
Industry Brief - Kyprolis Shows Superiority Over Velcade In Relapsed MM
Industry Brief - Bayer Halts Enrolment In Regorafenib Phase III Trial For CRC
Industry Brief - Pacritinib Phase III Trial Meets Primary Endpoint In MF

Table Of Contents

Key Pharma News 16 MARCH 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.